A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies

WT2725 is a Wilms’ tumor gene 1 (WT1)-derived-oligopeptide vaccine designed to induce WT1-specific cytotoxic T-lymphocytes against WT1(+) tumors in human leukocyte antigen (HLA)-A*0201(+) and/or HLA-A*0206(+) patients. Here, we report the results of a phase I study of WT2725. In this phase I, open-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Siqing, Piccioni, David E., Liu, Hongtao, Lukas, Rimas V., Kesari, Santosh, Aregawi, Dawit, Hong, David S., Yamaguchi, Kenichiro, Whicher, Kate, Zhang, Yi, Chen, Yu-Luan, Poola, Nagaraju, Eddy, John, Blum, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595891/
https://www.ncbi.nlm.nih.gov/pubmed/34785698
http://dx.doi.org/10.1038/s41598-021-01707-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595891/
https://www.ncbi.nlm.nih.gov/pubmed/34785698
http://dx.doi.org/10.1038/s41598-021-01707-3

Ejemplares similares